Related Experiment Videos
Hyperthermic intraoperative intreperitoneal chemotherapy (HIIC) with mitomycin C
P H Sugarbaker1, A M Averbach, P Jacquet
1Gastrointestinal Oncology Program, Washington Cancer Institute, Washington, DC, USA.
Surgical Technology International
|January 1, 1996
Summary
The peritoneal plasma barrier (PPB) limits chemotherapy drug absorption into the bloodstream after intraperitoneal administration. Understanding this barrier is crucial for optimizing cancer treatment delivery and efficacy.
Area of Science:
- Pharmacology
- Biomedical Engineering
- Oncology
Background:
- Intraperitoneal chemotherapy administration is a strategy to maximize drug concentration at the tumor site.
- Early mathematical models, such as Dedrick et al. (1978), laid the groundwork for understanding drug transport from the peritoneal cavity.
- Clinical and experimental studies have validated the theoretical basis of intraperitoneal drug delivery.
Purpose of the Study:
- To elucidate the pharmacokinetic principles governing drug transport from the peritoneal cavity to systemic circulation.
- To define and characterize the peritoneal plasma barrier (PPB) as a key factor in drug resorption.
- To provide a foundation for optimizing the use of intraperitoneal chemotherapy.
Main Methods:
- Review of existing mathematical models for drug transport.
- Analysis of pharmacokinetic data from clinical and experimental studies.
- Description of the anatomical and physiological components of the peritoneal plasma barrier.
Main Results:
- The peritoneal plasma barrier (PPB) significantly limits the systemic absorption of hydrophilic chemotherapeutic agents.
- The PPB is a complex diffusion barrier involving the peritoneum, interstitium, and fluid dynamics.
- Hydrophilic drugs like mitomycin C, doxorubicin, and cisplatin are particularly affected by the PPB.
Conclusions:
- The PPB is a critical determinant of drug bioavailability in intraperitoneal chemotherapy.
- Understanding the PPB is essential for designing effective drug delivery strategies and predicting treatment outcomes.
- Further research into modulating the PPB could enhance the efficacy of intraperitoneal cancer therapies.